Ginkgo Bioworks Holdings, Inc.

NYSE:DNA Rapport sur les actions

Capitalisation boursière : US$407.2m

Ginkgo Bioworks Holdings Gestion

Gestion contrôle des critères 3/4

Le PDG Ginkgo Bioworks Holdings est Jason Kelly, nommé en Jan2008, a un mandat de 16.83 ans. La rémunération annuelle totale est $ 262.50K, composée du salaire de 95.2% et des bonus 4.8%, y compris les actions et options de la société. détient directement 3.84% des actions de la société, d'une valeur de $ 15.63M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.3 ans et 2.7 ans.

Informations clés

Jason Kelly

Directeur général

US$262.5k

Rémunération totale

Pourcentage du salaire du PDG95.2%
Durée du mandat du directeur général16.8yrs
Propriété du PDG3.8%
Durée moyenne d'occupation des postes de direction6.3yrs
Durée moyenne du mandat des membres du conseil d'administration2.7yrs

Mises à jour récentes de la gestion

Recent updates

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Ginkgo Bioworks: Not Enough Progress

Nov 13

Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%

Oct 04
Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%

Ginkgo Bioworks: Here Comes The Test

Aug 22

The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%

Aug 16
The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%

Ginkgo Bioworks: Losing A Major Supporter

Jun 25

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump

Jun 18
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

May 11
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Ginkgo Bioworks: Broken Narrative

May 10

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Apr 26
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

Mar 06
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts

With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Mar 01
With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For

Ginkgo Bioworks: More Awful Revenue Guidance

Mar 01

Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment

Jan 26

Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty

Dec 20

Ginkgo Bioworks: A Long Way To Go

Nov 21

News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Nov 13
News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat

Ginkgo Bioworks: More Revenue Issues

Nov 13

Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Nov 10
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump

Porter's 5 Forces Suggest That Ginkgo Is A Buy

Oct 25

Ginkgo Bioworks: Products Progressing Towards Market

Oct 10

Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)

Aug 30

Ginkgo Bioworks: Lack Of Progress Is A Concern

Aug 18

Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)

Aug 10

Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds

Jun 23

Ginkgo Bioworks: Avoid For Now

Feb 20

Ginkgo: Standardizing Offerings For Growth

Feb 08

Ginkgo Bioworks: Increasing Focus On Pharma And Biotech

Jan 12

Analyse de la rémunération des PDG

Comment la rémunération de Jason Kelly a-t-elle évolué par rapport aux bénéfices de Ginkgo Bioworks Holdings?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$651m

Jun 30 2024n/an/a

-US$898m

Mar 31 2024n/an/a

-US$854m

Dec 31 2023US$263kUS$250k

-US$893m

Sep 30 2023n/an/a

-US$857m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$263kUS$250k

-US$2b

Sep 30 2022n/an/a

-US$4b

Jun 30 2022n/an/a

-US$3b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$381mUS$250k

-US$2b

Sep 30 2021n/an/a

-US$276m

Jun 30 2021n/an/a

-US$200m

Mar 31 2021n/an/a

-US$175m

Dec 31 2020US$11mUS$250k

-US$127m

Rémunération vs marché: La rémunération totale de Jason ($USD 262.50K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.18M ).

Rémunération et revenus: La rémunération de Jason a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Jason Kelly (43 yo)

16.8yrs

Titularisation

US$262,500

Compensation

Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Jason Kelly
Founder16.8yrsUS$262.50k3.84%
$ 15.6m
Reshma Shetty
Founder16.8yrsUS$262.50k4.18%
$ 17.0m
Mark Dmytruk
Chief Financial Officer4yrsUS$1.69m0.084%
$ 343.8k
Thomas Knight
Founderno datapas de donnéespas de données
Austin Che
Founderno datapas de données4.28%
$ 17.4m
Bartholomew Canton
Founderno datapas de données4.17%
$ 17.0m
Steven Coen
Chief Accounting Officer1.5yrspas de données0.012%
$ 47.2k
Karen Tepichin
General Counsel & Secretaryno datapas de donnéespas de données
Anna Wagner
Senior Vice President of Corporate Developmentno datapas de donnéespas de données
Samantha Sutton
Head of People6.8yrspas de donnéespas de données
Joshua Dunn
Head of Design6.1yrspas de donnéespas de données
Joaquim Marques
Head of Omics & Analytical Chemistry6.3yrspas de donnéespas de données

6.3yrs

Durée moyenne de l'emploi

43yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de DNA est chevronnée et expérimentée (6.3 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jason Kelly
Founder16.8yrsUS$262.50k3.84%
$ 15.6m
Reshma Shetty
Founder16.8yrsUS$262.50k4.18%
$ 17.0m
Norbert Bischofberger
Member of Biopharma Advisory Boardless than a yearpas de donnéespas de données
John M. Maraganore
Member of Biopharma Advisory Boardless than a yearpas de donnéespas de données
Harry Sloan
Independent Director3.2yrsUS$459.38k0.037%
$ 150.6k
Mark McCamish
Member of Biopharma Advisory Boardless than a yearpas de donnéespas de données
Christian O. Henry
Independent Director8.8yrsUS$477.50k0.060%
$ 244.8k
Kathy Hannan
Independent Director2.3yrsUS$448.67k0.0075%
$ 30.5k
Arie Belldegrun
Independent Director3.2yrsUS$457.50k0.031%
$ 127.0k
Shyam Sankar
Independent Chairman of the Board9.8yrsUS$485.19k0.11%
$ 450.0k
Jeff Legos
Member of Biopharma Advisory Boardless than a yearpas de donnéespas de données
Paolo Martini
Member of Biopharma Advisory Boardless than a yearpas de donnéespas de données

2.7yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la DNA n'est pas considéré comme expérimenté ( 2.7 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.